

Published by
Ministry of Health, Labour and Welfare



Translated by
Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Rabeprazole sodium/amoxicillin hydrate/metronidazole

November 16, 2022

Therapeutic category

Other antibiotic preparations

Non-proprietary name

Rabeprazole sodium/amoxicillin hydrate/metronidazole

Safety measure

Precautions should be revised in the package insert.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Electronic Package Inserts of Prescription Drugs, etc. PSEHB Notification No. 0611-1 by the Director of Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 11, 2021 (New instructions): Revised language is underlined.

Current	Revision
<p>8. IMPORTANT PRECAUTIONS</p> <p><Amoxicillin hydrate></p> <p>Shock <u>may occur</u>. A thorough medical interview should be conducted.</p> <p>11. ADVERSE REACTIONS</p> <p>11.1 Clinically Significant Adverse Reactions</p> <p><Amoxicillin hydrate></p> <p>(N/A)</p>	<p>8. IMPORTANT PRECAUTIONS</p> <p><Amoxicillin hydrate></p> <p><u>No methods are currently available for predicting onset of shock, anaphylaxis, or acute coronary syndrome accompanying allergic reaction with reasonable certainty.</u> A thorough medical interview should be conducted <u>regarding patient's medical history of these events, etc. in advance.</u> In addition, it should be ensured that a <u>history of allergy to antibiotics was checked.</u></p> <p>11. ADVERSE REACTIONS</p> <p>11.1 Clinically Significant Adverse Reactions</p> <p><Amoxicillin hydrate></p> <p><u>Acute coronary syndrome accompanying allergic reaction</u></p>

(N/A): Not Applicable. No corresponding language is included in the current Precautions.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
 E-mail: safety.info@pmda.go.jp